This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZEAL Zealand Pharma A/S (ZEAL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Zealand Pharma A/S Stock (NASDAQ:ZEAL) 30 days 90 days 365 days Advanced Chart Get Zealand Pharma A/S alerts:Sign Up Key Stats Today's Range$17.59▼$17.5950-Day Range$16.54▼$19.2052-Week Range$9.93▼$32.94VolumeN/AAverage Volume4,965 shsMarket Capitalization$818.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewZealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.Read More… Receive ZEAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ZEAL Stock News HeadlinesZealand Pharma says obesity drug deal with Roche will help it stay independentApril 27 at 12:21 AM | ft.comZealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetesApril 24, 2025 | globenewswire.comCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…April 28, 2025 | Crypto Swap Profits (Ad)Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discoveryApril 23, 2025 | globenewswire.comZealand Pharma launches long-term incentive programs for board of directorsApril 20, 2025 | msn.comTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsApril 19, 2025 | globenewswire.comZealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2025April 19, 2025 | globenewswire.comResolutions from Zealand Pharma's Annual General Meeting 2025March 27, 2025 | globenewswire.comSee More Headlines ZEAL Stock Analysis - Frequently Asked Questions How were Zealand Pharma A/S's earnings last quarter? Zealand Pharma A/S (NASDAQ:ZEAL) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($4.61) earnings per share for the quarter, beating the consensus estimate of ($6.31) by $1.70. The company had revenue of $16.87 million for the quarter, compared to analyst estimates of $12.21 million. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 111.04% and a negative net margin of 565.44%. When did Zealand Pharma A/S IPO? Zealand Pharma A/S (ZEAL) raised $75 million in an initial public offering (IPO) on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. What other stocks do shareholders of Zealand Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zealand Pharma A/S investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), Editas Medicine (EDIT), Spectrum Pharmaceuticals (SPPI), AbbVie (ABBV) and CRISPR Therapeutics (CRSP). Company Calendar Last Earnings11/10/2021Today4/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ZEAL CIK1674988 Webwww.zealandpharma.com Phone(458) 877-3600Fax45-8877-3898Employees355Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-161,990,000.00 Net Margins-565.44% Pretax Margin-364.34% Return on Equity-111.04% Return on Assets-56.54% Debt Debt-to-Equity Ratio0.93 Current Ratio4.79 Quick Ratio4.78 Sales & Book Value Annual Sales$46.54 million Price / Sales17.59 Cash FlowN/A Price / Cash FlowN/A Book Value$3.38 per share Price / Book5.20Miscellaneous Outstanding Shares46,538,000Free Float45,514,000Market Cap$818.60 million OptionableNot Optionable Beta1.45 Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ZEAL) was last updated on 4/28/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredThe Silent Heist Draining Your Retirement SavingsU.S. Debt Crisis - A Silent Heist of Your Retirement Savings Americans are losing wealth daily and don't ev...American Hartford Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zealand Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Zealand Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.